Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 17K | 0 | 0 | 86K | 0 |
| Gross Profit | -827K | -16K | -15K | 71K | -7K |
| Operating Income | -5M | -15M | -10M | -9M | -7M |
| EBITDA | -4M | -15M | -10M | -9M | -7M |
| Net Income | -5M | -15M | -9M | -9M | -7M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.65
-10.81% today
1Y Change
-77.40%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PRF Technologies Ltd. (PRFX) is a Healthcare stock with listed on NASDAQ. The stock last traded around $1.65 and down 77.4% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +99.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +99.1%, free cash flow +68.7% with operating margin 0.0% and ROIC -33.9%. Stock Foundry combines PRFX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRFX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PRFX Max Drawdown
-88.69%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PRFX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$7.2M
+17.6% YoY
Free Cash Flow
-$6.6M
-2.1% YoY
Revenue Growth
+0.0%
EPS Growth
+99.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 17K | 0 | 0 | 86K | 0 |
| Gross Profit | -827K | -16K | -15K | 71K | -7K |
| Operating Income | -5M | -15M | -10M | -9M | -7M |
| EBITDA | -4M | -15M | -10M | -9M | -7M |
| Net Income | -5M | -15M | -9M | -9M | -7M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4M | 4M | 8M | 4M | 17M |
| Total Assets | 12M | 5M | 10M | 12M | 19M |
| Total Liabilities | 3M | 3M | 3M | 1M | 991K |
| Shareholder Equity | 9M | 2M | 7M | 11M | 18M |
| Total Debt | 21K | 45K | 86K | 0 | 0 |
| Net Debt | -4M | -4M | -8M | -4M | -17M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
7M
-1.5% YoY
Capital Expenditures
50K
-733.3% YoY
Free Cash Flow
7M
-2.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-47.0%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.